Dr. Daniela Matei Appointed Director of Houston Methodist Neal Cancer Center, Advancing Translational Oncology Research to New Heights
Houston Methodist has announced a landmark appointment in the field of oncology research and clinical care. Dr. Daniela Matei, an internationally acclaimed cancer clinician and translational scientist, will assume the directorship of the prestigious Dr. Mary and Ron Neal Cancer Center starting April 2026. This leadership transition follows an extensive national search to secure a visionary whose expertise spans cutting-edge ovarian cancer biology and precision therapeutics.
Having dedicated over two decades to unraveling the complexities of ovarian cancer pathophysiology, Dr. Matei emerges as a leading figure in bridging laboratory innovation with clinical application. Currently, she serves as chief of the Division of Reproductive Science in Medicine within Northwestern University Feinberg School of Medicine’s Department of Obstetrics and Gynecology. Additionally, she spearheads the Translational Research in Malignancies Program at the Robert H. Lurie Comprehensive Cancer Center. Her dual roles underscore a career anchored in advancing multidisciplinary cancer research.
Dr. Matei’s contributions to the molecular understanding of ovarian cancer resistance mechanisms have reshaped therapeutic paradigms. With a prolific publication record exceeding 170 peer-reviewed manuscripts and an impressive citation count surpassing 15,000, her research elucidates tumor microenvironment dynamics and novel pathways critical to tumorigenesis and metastasis. Particularly, her work disentangles chemoresistance pathways, providing strategic targets for next-generation targeted therapies.
An expert clinical trialist, Matei has led numerous hypothesis-driven trials investigating novel agents and combination regimens in gynecologic malignancies. Her trials often integrate multi-omics approaches that stratify patients by molecular profiles, optimizing precision medicine strategies. These efforts have progressively transformed standard-of-care protocols, enabling personalized interventions based on tumor genomics and immunologic signatures.
Her leadership extends to national and international cancer research governance. Dr. Matei has contributed extensively to committees of the National Cancer Institute, shaping research priorities and policies that influence funding and clinical trial design. Her involvement with the American Society of Clinical Oncology, the Ovarian Cancer NCI Taskforce, Gynecologic Oncology Group (now NRG Oncology), and the National Comprehensive Cancer Network highlights a sustained commitment to translating scientific discoveries into clinical guidelines.
Marc L. Boom, M.D., president and CEO of Houston Methodist, expressed tremendous enthusiasm about Dr. Matei’s appointment. He emphasized that her expertise in translational science and precision oncology will significantly propel Houston Methodist’s commitment to innovation. Dr. Matei’s leadership is poised to foster an ecosystem that supports cutting-edge research and enhances outcomes for cancer patients locally, statewide, and globally.
Dr. Matei succeeds Dr. Nestor Esnaola, who served in an interim capacity since January 2025 after Dr. Jenny Chang transitioned to lead the Houston Methodist Academic Institute. Dr. Chang underscored Dr. Matei’s exceptional skill in deciphering ovarian cancer resistance mechanisms and translating basic research into impactful clinical trials. Chang articulated high expectations that Dr. Matei’s vision will invigorate the center’s academic and clinical mission, seamlessly converting scientific breakthroughs into tangible patient benefits.
Dr. Matei is committed not only to advancing translational oncology but also to cultivating the next generation of medical scientists and clinicians. She prioritizes mentoring students, fellows, residents, and junior faculty, fostering a collaborative environment conducive to innovative cancer research and education. This holistic approach ensures sustainability in achieving long-term breakthroughs and clinical excellence.
Her appointment is bolstered by a substantial award from the Cancer Prevention and Research Institute of Texas (CPRIT), which granted $4 million under a Recruitment of Established Investigator (REI) award. This funding will enhance research infrastructure, support high-impact projects, and drive accelerated discovery of novel therapeutic interventions against gynecologic cancers.
Dr. Matei’s educational journey began with her medical degree from the Carol Davila University of Medicine and Pharmacy in Bucharest, Romania. She further honed her expertise through postgraduate training at SUNY Stony Brook and completed a fellowship in hematology and oncology at the University of California, Los Angeles. These formative experiences laid a strong foundation for her subsequent achievements in oncology research and clinical practice.
In her new capacity, Dr. Matei will champion an integrative research agenda that blends molecular biology, immunotherapy, and state-of-the-art clinical trial methodologies. She envisions a translational continuum where patient-derived biological insights rapidly inform therapeutic innovations, thereby shortening the time from bench to bedside.
This leadership change heralds a new era for the Houston Methodist Neal Cancer Center, positioning it at the forefront of gynecologic oncology research and patient-centered care. Dr. Matei’s pioneering work exemplifies the transformative potential of combining scientific rigor with compassionate clinical stewardship in the fight against cancer.
As her tenure begins, colleagues and patients alike anticipate a period of dynamic growth, enhanced interdisciplinary collaboration, and groundbreaking discoveries under Dr. Matei’s guidance. Her appointment reinforces Houston Methodist’s status as a beacon of hope and excellence in cancer treatment and research worldwide.
Subject of Research:
Ovarian cancer biology, mechanisms of chemoresistance, translational oncology, precision medicine, gynecologic cancer clinical trials.
Article Title:
Dr. Daniela Matei to Lead Houston Methodist Neal Cancer Center: A New Frontier in Translational Ovarian Cancer Research
News Publication Date:
February 27, 2026
Web References:
https://www.houstonmethodist.org/newsroom/
X: https://x.com/MethodistHosp
Facebook: https://www.facebook.com/houstonmethodist/
LinkedIn: https://www.linkedin.com/company/houston-methodist/posts/?feedView=all
Instagram: https://www.instagram.com/houstonmethodist/
TikTok: https://www.tiktok.com/@houstonmethodist
On Health Blog: https://www.houstonmethodist.org/blog/
Leading Medicine Blog: https://www.houstonmethodist.org/leading-medicine-blog/
Keywords:
Ovarian cancer, translational research, chemoresistance, precision oncology, gynecologic cancer, clinical trials, molecular oncology, cancer therapeutics, cancer biology, hematology-oncology, clinical scientist, medical research leadership
